Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer.

Xiaoyu ZhaiRuoxi HongYing FanPeng YuanJiayu WangDie SangJunlin ChenChunying ZhaoKaiping OuFei MaBing-He Xu

Published in: Thoracic cancer (2018)

Weekly low-dose bevacizumab combined with chemotherapy shows a relatively favorable clinical response and tolerable toxicity, providing a feasible option for heavily pretreated MBC patients.

Keyphrases

low dose
metastatic breast cancer
end stage renal disease
high dose
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
metastatic colorectal cancer
squamous cell carcinoma
patient reported outcomes